Cost of pain medication to treat adult patients with nonmalignant chronic pain in the United States
- PMID: 25166291
- PMCID: PMC10438355
- DOI: 10.18553/jmcp.2014.20.9.921
Cost of pain medication to treat adult patients with nonmalignant chronic pain in the United States
Abstract
Background: Nonmalignant chronic pain (NMCP) is a public health concern. Among primary care appointments, 22% focus on pain management. The American Academy of Pain Medicine guidelines for NMCP recommend combination medication therapy (including analgesics, nonsteroidal anti-inflammatory drugs [NSAIDs], opioids, antidepressants, and anticonvulsants) as a key component to effective treatment for many chronic pain diagnoses. However, there has been little evidence outlining the costs of pain medications in adult patients with NMCP in the United States, an area that necessitates further consideration as the nation moves toward value-based benefit design.
Objectives: To estimate the cost of pain medication attributable to treating adult patients with NMCP in the United States and to analyze the trend of outpatient pain visits.
Methods: This cross-sectional study used the National Ambulatory Medical Care Survey (NAMCS) data from 2000-2007. The Division of Health Care Statistics, National Center for Health Statistics, and the Centers for Disease Control and Prevention conducted the survey. The study included patients aged ≥18 years with chronic pain diagnoses (identified by the ICD-9-CM codes: primary, secondary, and tertiary). Patients prescribed at least 1 pain medication were included in the cost analysis. Pain-related prescription medications prescribed during ambulatory care visits were retrieved by using NAMCS drug codes/National Drug Code numbers. National pain prescription frequencies (weighted) were obtained from NAMCS data, using the statistical software STATA. We created pain therapy categories (drug classes) for cost analysis based on national pain guidelines. Drug classes used in this analysis were opioids/opioid-like agents, analgesics/NSAIDs, tricyclic antidepressants, selective serotonin reuptake inhibitors, antirheumatics/immunologics, muscle relaxants, topical products, and corticosteroids. We calculated average prices based on the 3 lowest average wholesale prices reported in the Red Book 2009 for maximum recommended daily dose. Total pain medication costs were calculated in 2009 and 2013 dollar values. The study analyzed NMCP-related outpatient visit trends and used time series analysis to forecast visits using U.S. population data and statistics.
Results: The total costs of prescription medications prescribed for pain were $17.8 billion annually in the United States. Cost estimates were captured based on a total of 690,205,290 (~690 million) weighted outpatient visits made for chronic pain from 2000 to 2007 in the United States. Of those patients, 99% received a medication that could be used for NMCP. Among the patients, 29% reported taking ≥5 medications. A linear trend of pain visits is visible, reporting change (from 11% to 14%) from 2000 to 2007 in the United States. All agents except opioids/opioid-like agents and analgesics/NSAIDs were further categorized as adjuvant therapy to create 3 major drug class categories. The largest 3 categories of pain therapy for the United States (annually) were analgesics/NSAIDs ($1.9 billion), opioids ($3.6 billion), and adjuvants ($12.3 billion). Despite having the highest prescription frequency nationally, analgesics/NSAIDS accounted for about 11% of the overall pain medication costs. This study found that adjuvant therapy accounted for 69% of the total pain medication costs. Among adjuvants, 33.5% of the cost was contributed by antirheumatics/immunologics. Other adjuvants included muscle relaxants (4.4%), topical products (8.6%), and corticosteroids (9.4%).
Conclusions: This study demonstrated national prescribing costs and use within various drug categories of pain medications in a large outpatient population over an 8-year period in the United States. Policymakers, stakeholders, and health plan decision makers may consider this cost analysis, since they need to know how drug costs are being allocated. Moreover, information about costs and use of pain medications is valuable for the practitioner making individual patient care decisions, as well as for those who make population based decisions. This study reported an increasing trend of outpatient pain visits in the United States. Therefore, policymakers and health plan decision makers may expect a growing number of pain-related outpatient visits in coming years and allocate resources accordingly to meet the need.
Similar articles
-
Determinants of Opioid Prescribing for Nonmalignant Chronic Pain in US Outpatient Settings.Pain Med. 2018 Mar 1;19(3):524-532. doi: 10.1093/pm/pnx025. Pain Med. 2018. PMID: 28340230
-
Pharmacoeconomic Analysis of Pain Medications Used to Treat Adult Patients with Chronic Back Pain in the United States.J Pain Palliat Care Pharmacother. 2016 Dec;30(4):300-307. doi: 10.1080/15360288.2016.1231735. Epub 2016 Oct 17. J Pain Palliat Care Pharmacother. 2016. PMID: 27749151
-
Opioid prescribing patterns for non-malignant chronic pain for rural versus non-rural US adults: a population-based study using 2010 NAMCS data.BMC Health Serv Res. 2014 Nov 19;14:563. doi: 10.1186/s12913-014-0563-8. BMC Health Serv Res. 2014. PMID: 25407745 Free PMC article.
-
Palliative Treatment of Cancer-Related Pain [Internet].Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2005 Dec. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 09-2005. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2005 Dec. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 09-2005. PMID: 29320015 Free Books & Documents. Review.
-
Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline.Ann Intern Med. 2007 Oct 2;147(7):505-14. doi: 10.7326/0003-4819-147-7-200710020-00008. Ann Intern Med. 2007. PMID: 17909211 Review.
Cited by
-
Efficacy and results of virtual nursing intervention for cancer patients: A systematic review and meta-analysis.Asia Pac J Oncol Nurs. 2024 May 14;11(7):100515. doi: 10.1016/j.apjon.2024.100515. eCollection 2024 Jul. Asia Pac J Oncol Nurs. 2024. PMID: 39050110 Free PMC article. Review.
-
The use of healthcare services and disabling chronic pain: results from the cross-sectional population-based Andalusian Health Survey.Eur J Public Health. 2024 Aug 1;34(4):639-645. doi: 10.1093/eurpub/ckae079. Eur J Public Health. 2024. PMID: 38750626 Free PMC article.
-
Sleep hygiene strategies for individuals with chronic pain: a scoping review.BMJ Open. 2023 Feb 2;13(2):e060401. doi: 10.1136/bmjopen-2021-060401. BMJ Open. 2023. PMID: 36731933 Free PMC article. Review.
-
A Comparison of Institutional Opioid Equianalgesia Tools: A National Study.J Palliat Med. 2022 Nov;25(11):1686-1691. doi: 10.1089/jpm.2021.0678. Epub 2022 May 13. J Palliat Med. 2022. PMID: 35559657 Free PMC article.
-
Oleanolic acid administration alleviates neuropathic pain after a peripheral nerve injury by regulating microglia polarization-mediated neuroinflammation.RSC Adv. 2020 Apr 1;10(22):12920-12928. doi: 10.1039/c9ra10388k. eCollection 2020 Mar 30. RSC Adv. 2020. PMID: 35492085 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical